FindTrial
Sign In

THE-630

DRUG2 trials

Sponsors

Theseus Pharmaceuticals Inc., Theseus Pharmaceuticals

Conditions

Digestive System DiseaseDigestive System NeoplasmGastrointestinal DiseasesGastrointestinal NeoplasmsGastrointestinal Stromal Tumors (GIST)NeoplasmsNeoplasms by Histologic TypeNeoplasms, Connective Tissue

Phase 1

A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
TerminatedNCT05160168
Theseus PharmaceuticalsDigestive System Disease, Digestive System Neoplasm, Gastrointestinal Diseases +6
Start: 2022-01-03End: 2024-02-02Updated: 2024-06-05
A Phase 1/2 Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of the Oral KIT Inhibitor THE-630 in Patients with Advanced Gastrointestinal Stromal Tumors (GIST)
CompletedCTIS2022-502087-21-00
Theseus Pharmaceuticals Inc.Gastrointestinal Stromal Tumors (GIST)
End: 2023-07-13Target: 37Updated: 2023-06-05

Related Papers

Initial results from the phase (ph) 1 portion of a ph 1/2 study of THE-630 in patients (pts) with advanced gastrointestinal stromal tumor (GIST).
Journal of Clinical Oncology2023-06-012 citations